Enovis Corporation
ENOVHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeEnovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. The company carries a $1.31B market cap, placing it firmly in the small-cap category. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Market Cap
$1.31B
Beta
1.52
P/E (TTM)
—
P/E (Fwd)
5.58
EPS (TTM)
$-19.89
EPS (Fwd)
$4.06
ROE
-55.4%
ROA
1.1%
Cash
$33.1M
Total Debt
$1.41B
Free CF
$206.9M
52W Change
-23.5%
Annual Financials
Cash vs Debt
On the balance sheet, ENOV has $33.1M in cash with $1.41B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $206.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -55.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.56B (2022) to $2.25B (2025), reflecting a 44% increase over the period.
A beta of 1.52 means ENOV is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Enovis Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Enovis Corporation's trajectory.